3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Acrocephalosyndactylia
6
Cholangiocarcinoma
4
Neoplasm Metastasis
3
Myeloproliferative Disorders
2
Endometrial Neoplasms
2
Carcinoma, Transitional Cell
2
Stomach Neoplasms
1
Solid Tumor
1
Recurrence
1
Oligodendroglioma
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Multiple Myeloma
1
Lung Neoplasms
1
Glioma
1
Glioblastoma
1
Eosinophilia
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Advanced Malignancies
1
Interventions
Carboplatin
367
Pemetrexed
308
pembrolizumab
302
Cisplatin
242
Paclitaxel
230
Docetaxel
199
Gemcitabine
130
Nivolumab
121
Erlotinib Hydrochloride
114
Bevacizumab
85
osimertinib
78
atezolizumab
65
durvalumab
58
Cetuximab
57
130-nm albumin-bound paclitaxel
56
Gefitinib
52
Ipilimumab
46
Afatinib
38
Drug Therapy
33
Cyclophosphamide
30
Crizotinib
30
Albumin-Bound Paclitaxel
30
Vinorelbine
28
cemiplimab
26
tislelizumab
25
avelumab
23
icotinib
22
Radiotherapy
22
capmatinib
21
Oxaliplatin
21
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Carcinoma, Non-Small-Cell Lung
×
pemigatinib
×
Clear all
NCT05253807
2025-08-05
FIGHT-210
Incyte Corporation
Phase 2
Completed
8 enrolled
13 charts